{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:45:00Z","timestamp":1793047500902,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["75N95022D00017"],"award-info":[{"award-number":["75N95022D00017"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA015831"],"award-info":[{"award-number":["UG1DA015831"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["75N95020D00012"],"award-info":[{"award-number":["75N95020D00012"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["75N95019D00013"],"award-info":[{"award-number":["75N95019D00013"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["75N95024D00037"],"award-info":[{"award-number":["75N95024D00037"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.josat.2025.209854","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T23:10:04Z","timestamp":1765149004000},"page":"209854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A clinical trial loses access to some of its experimental treatment conditions: What can be done?"],"prefix":"10.1016","author":[{"given":"Sarah","family":"Meyers-Ohki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matisyahu","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Provost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Otterstatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2025.209854_bb0005","author":"Camurus"},{"issue":"7","key":"10.1016\/j.josat.2025.209854_bb0010","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1176\/appi.ajp.2008.07111835","article-title":"Computer-assisted delivery of cognitive-behavioral therapy for addiction: A randomized trial of CBT4CBT","volume":"165","author":"Carroll","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1016\/j.josat.2025.209854_bb0015","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The role of behavioral interventions in buprenorphine maintenance treatment: A review","volume":"174","author":"Carroll","year":"2017","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/j.josat.2025.209854_bb0020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1037\/a0037496","article-title":"Adding an internet-delivered treatment to an efficacious treatment package for opioid dependence","volume":"82","author":"Christensen","year":"2014","journal-title":"Journal of Consulting and Clinical Psychology"},{"key":"10.1016\/j.josat.2025.209854_bb0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jclinepi.2022.11.002","article-title":"An overview of methodological considerations regarding adaptive stopping, arm dropping, and randomization in clinical trials","volume":"153","author":"Granholm","year":"2023","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.josat.2025.209854_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108447","article-title":"Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse","volume":"131","author":"Greiner","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2025.209854_bb0035","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.josat.2025.209854_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.josat.2025.209854_bb0045","first-page":"91","article-title":"What are the implications of the STAR*D trial for primary care? A review and synthesis","volume":"10","author":"Huynh","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.josat.2025.209854_bb0050","series-title":"Pear therapeutics files for bankruptcy as CEO blames shortfalls on insurers. Forbes","author":"Jennings","year":"2023"},{"issue":"3","key":"10.1016\/j.josat.2025.209854_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"10118","key":"10.1016\/j.josat.2025.209854_bb0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.josat.2025.209854_bb0065","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.josat.2025.209854_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2017.04.016","article-title":"Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone","volume":"85","author":"Nunes","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209854_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2025.107816","article-title":"Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)","volume":"150","author":"Shulman","year":"2025","journal-title":"Contemporary Clinical Trials"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925002334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925002334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:10:31Z","timestamp":1773882631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925002334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":15,"alternative-id":["S2949875925002334"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209854","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A clinical trial loses access to some of its experimental treatment conditions: What can be done?","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209854"}}